286 related articles for article (PubMed ID: 18821585)
21. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication.
Uddin S; Bavi PP; Hussain AR; Alsbeih G; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Ahmed M; Al-Kuraya KS
Carcinogenesis; 2009 Nov; 30(11):1832-40. PubMed ID: 19520793
[TBL] [Abstract][Full Text] [Related]
22. Identification of proteins secreted from leptin stimulated MCF-7 breast cancer cells: a dual proteomic approach.
Perera CN; Spalding HS; Mohammed SI; Camarillo IG
Exp Biol Med (Maywood); 2008 Jun; 233(6):708-20. PubMed ID: 18408141
[TBL] [Abstract][Full Text] [Related]
23. Effect of obesity on breast cancer development.
Cleary MP; Grossmann ME; Ray A
Vet Pathol; 2010 Mar; 47(2):202-13. PubMed ID: 20124008
[TBL] [Abstract][Full Text] [Related]
24. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro.
Wang XY; Tan JX; Vasse M; Delpech B; Ren GS
Chin Med J (Engl); 2009 Jun; 122(11):1300-4. PubMed ID: 19567141
[TBL] [Abstract][Full Text] [Related]
25. Obesity-induced metabolic stresses in breast and colon cancer.
Sung MK; Yeon JY; Park SY; Park JH; Choi MS
Ann N Y Acad Sci; 2011 Jul; 1229():61-8. PubMed ID: 21793840
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
Himpe E; Kooijman R
Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
[TBL] [Abstract][Full Text] [Related]
28. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
29. [Dual effects of androgens on mammary gland].
Brettes JP; Mathelin C
Bull Cancer; 2008 May; 95(5):495-502. PubMed ID: 18541513
[TBL] [Abstract][Full Text] [Related]
30. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma.
Caldefie-Chézet F; Damez M; de Latour M; Konska G; Mishellani F; Fusillier C; Guerry M; Penault-Llorca F; Guillot J; Vasson MP
Biochem Biophys Res Commun; 2005 Sep; 334(3):737-41. PubMed ID: 16009333
[TBL] [Abstract][Full Text] [Related]
31. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
32. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.
Sauvé K; Lepage J; Sanchez M; Heveker N; Tremblay A
Cancer Res; 2009 Jul; 69(14):5793-800. PubMed ID: 19584281
[TBL] [Abstract][Full Text] [Related]
33. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Saxena NK; Taliaferro-Smith L; Knight BB; Merlin D; Anania FA; O'Regan RM; Sharma D
Cancer Res; 2008 Dec; 68(23):9712-22. PubMed ID: 19047149
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
[TBL] [Abstract][Full Text] [Related]
35. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
[TBL] [Abstract][Full Text] [Related]
37. A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo.
Catalano S; Leggio A; Barone I; De Marco R; Gelsomino L; Campana A; Malivindi R; Panza S; Giordano C; Liguori A; Bonofiglio D; Liguori A; Andò S
J Cell Mol Med; 2015 May; 19(5):1122-32. PubMed ID: 25721149
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
39. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status.
Ray A; Nkhata KJ; Cleary MP
Int J Oncol; 2007 Jun; 30(6):1499-509. PubMed ID: 17487372
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
